Flavoxate HCl(Rec-7-0040 DW61)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
包装与价格：
| 包装 | 价格(元) |
| 250mg | 询价 |
| 500mg | 询价 |
| 1g | 询价 |
| 2g | 询价 |
| 5g | 询价 |
| 10g | 询价 |
| 25g | 询价 |
理化性质和储存条件
| Molecular Weight (MW) | 427.92 |
|---|
| Formula | C24H25NO4.HCl |
|---|
| CAS No. | 3717-88-2 |
|---|
| Storage | -20℃ for 3 years in powder form |
|---|
| -80℃ for 2 years in solvent |
| Solubility (In vitro) | DMSO: 3 mg/mL (7.0 mM) |
|---|
| Water: 10 mg/mL (23.4 mM) |
| Ethanol: <1 mg/mL |
| Solubility (In vivo) | 30% Propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL |
|---|
| Synonyms | Rec-7-0040; DW-61; NSC-114649; Rec 7-0040; DW 61; NSC 114649; Rec7-0040; DW61; NSC114649 |
|---|
实验参考方法
| In Vitro | In vitro activity: Flavoxate displaces [3H]nitrendipine on the Ca2+ channels binding sites with IC50 of 254 μM. Flavoxate (>10 μM) suppresses carbachol-induced contractions in isolated rat detrusor strips with pD value of 4.55. Flavoxate (>10 μM) suppresses Ca2+-induced contractions in isolated rat detrusor strips with pIC50 value of 4.92. Flavoxate (0.01 μM –10 μM) inhibits CAMP formation in a concentration-dependent manner in membranes from the rat striatum and cerebral cortex, an action which is completely abolished by pretreating the membranes with pertussis toxin (PTX). Flavoxate causes a concentration-dependent reduction of the K+-induced contraction of human urinary bladder. Flavoxate inhibits the peak amplitude of voltage-dependent nifedipine-sensitive inward Ba2+ currents in a voltage- and concentration-dependent manner with Ki value of 10 μM in human detrusor myocytes. |
|---|
| In Vivo | Flavoxate (10mg/kg) suppresses both the an initial, rapidly rising phasic contraction (phase 1) and the tonic contraction (phase 2) contractions to the same extent in rats. Flavoxate (10mg/kg) abolishes the bladder contractions without causing any change in the amplitude of the contractions in rats. Flavoxate (3 mg/kg) abolishes the efferent neural activity and the associated bladder contractions for about 10 minutes without changing the baseline vesical pressure in rats. ICV-injected (50 to 200 μg/rat) or IT-injected (100 to 200 μg/rat) Flavoxate abolishes rhythmic bladder contractions during and after injection for five to 15 minutes in a dose-dependent manner in rats. Flavoxate (3 mg/kg, i.v.) abolishes rhythmic bladder contractions and the maximal intervals of voiding contractions is 7.20 min. |
|---|
| Animal model | Sprague-Dawley rats |
|---|
| Formulation & Dosage | Dissolved in saline; 10 mg/kg; i.v. injection |
|---|
| References | Int J Urol. 1996 May;3(3):218-27; Brain Res. 1996 Jul 15;727(1-2):91-8. |
|---|
